Abstract:The use of existing mouse models in cancer research is of utmost importance as they aim to explore the casual link between candidate cancer genes and carcinogenesis as well as to provide models to develop and test new therapies. However, faster progress in translating mouse cancer model research into the clinic has been hampered due to the limitations of these models to better reflect the complexities of human tumors. Traditionally, immunocompetent and immunodeficient mice with syngeneic and xenografted tumors transplanted subcutaneously or orthotopically have been used. These models are still being widely employed for many different types of studies, in part due to their widespread availability and low cost. Other types of mouse models used in cancer research comprise transgenic mice in which oncogenes can be constitutively or conditionally expressed and tumor-suppressor genes silenced using conventional methods, such as retroviral infection, microinjection of DNA constructs, and the so-called "gene-targeted transgene" approach. These traditional transgenic models have been very important in studies of carcinogenesis and tumor pathogenesis, as well as in studies evaluating the development of resistance to therapy. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing approach has revolutionized the field of mouse cancer models and has had a profound and rapid impact on the development of more effective systems to study human cancers. The CRISPR/Cas9-based transgenic models have the capacity to engineer a wide spectrum of mutations found in human cancers and provide solutions to problems that were previously unsolvable. Recently, humanized mouse xenograft models that accept patient-derived xenografts and CD34+ cells were developed to better mimic tumor heterogeneity, the tumor microenvironment, and cross-talk between the tumor and stromal/immune cells. These features make them extremely valuable models for the evaluation of investigational cancer therapies, specifically new immunotherapies. Taken together, improvements in both the CRISPR/Cas9 system producing more valid mouse models and in the humanized mouse xenograft models resembling complex interactions between the tumor and its environment might represent one of the successful pathways to precise individualized cancer therapy, leading to improved cancer patient survival and quality of life.

Translating Human Cancer Sequences into Personalized Porcine Cancer Models

Translational Relevance and Future Integration of the Oncopig Cancer Model in Preclinical Applications

Genetic Engineering Drives the Breakthrough of Pig Models in Liver Disease Research☆

Pigs as clinically relevant models for synergizing interventional oncology and immunotherapy

Patient-derived Xenograft Models in Hepatopancreatobiliary Cancer

Pigs: Large Animal Preclinical Cancer Models

The Oncopig as an Emerging Model to Investigate Copper Regulation in Cancer

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Benefits and opportunities of the transgenic Oncopig cancer model

Characterization of A Bronchoscopically Induced Transgenic Lung Cancer Pig Model for Human Translatability

Advances in Prostate Cancer Research Models: from Transgenic Mice to Tumor Xenografting Models

The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies

Animal models for modeling pancreatic cancer and novel drug discovery

Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic

CRISPR/Cas9-Mediated Gene Editing in Porcine Models for Medical Research

Canine as a Comparative and Translational Model for Human Mammary Tumor

Transgenic Mouse Models in Cancer Research

Humanized Rodent Models for Cancer Research

Application of Laboratory Animal Models in Cancer Precision Medicine Research

Patient-Derived Xenograft Platform of Oscc: A Renewable Human Bio-Bank for Preclinical Cancer Research and A New Co-Clinical Model for Treatment Optimization